Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 645-650

  Brandes, Alba A ^a   Ermani, Mario ^a   Turazzi, Sergio ^a   Scelzi, Elvira ^a   Berti, Franco ^a   Amistà, Pietro ^a   Rotilio, Antonino ^a   Licata, Claudio ^a   Fiorentino, Mario V ^a  

^a Azienda Ospedaliera   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROCARBAZINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN ALLERGY;

EID: 0032975369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.645     Document Type: Article

References (38)

1. Brandes AA, Fiorentino M: The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Invest 14:547-555, 1996
2. 6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts. J Neurosurg 70:573-577, 1989
3. 6-alkylguanine-DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 7:879-883, 1986
4. Newton HB, Bromberg J, Junck L, et al: Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neurooncol 15:257-263, 1993
5. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31:717-724, 1992
6. Couldwell WT, Joon HU, Antel JP, et al: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29:880-887, 1991
7. Pollack IF, Randall MS, Kristofik MP, et al: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990
8. Vertosick FT, Selker RG, Randall MS, et al: A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol 19:97-103, 1994
9. O'Brian CA, Liskamp RM, Solomon DH, et al: Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465, 1985
10. Baltuch GH, Couldwell WT, Villemure JG, et al: Protein kinase C inhibitors suppress cell growth in established and low passage glioma cell lines: A comparison between staurosporine and tamoxifen. Neurosurgery 33:495-501, 1993
11. Lien EA, Wester K, Lonning PE, et al: Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63:641-645, 1991
12. Couldwell WT, Weiss MH, De Giorgio CM, et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high dose tamoxifen. Neurosurgery 32:485-490, 1993
13. Burger PC: Malignant astrocytic neoplasms: Classification, pathology, anatomy and response to treatment. Semin Oncol 13:16-26, 1983
14. Macdonald DR, Cascino TL, Schold C, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment [WHO Offset Publication No. 48]. Neoplasma 20:37-46, 1980
16. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
17. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
18. Ameri A, Poisson M, Chauveinc L, et al: Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: A phase II study. J Neurooncol 32:155-160, 1997
19. Jeremic B, Grujicic D, Jevremovic S, et al: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10:1074-1077, 1992
20. Coyle T, Baptista J, Winfield J, et al: Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high grade glioma in adults: A phase II study. J Clin Oncol 8:2014-2018, 1990
21. Buckner JC, Burch PA, Schaefer PL, et al: Phase II trial of nitrogen mustard, vincristine and procarbazine in patients with recurrent glioma: NCCTG results. Proc Am Soc Clin Oncol 15:155, 1996 (abstr 283)
22. Kyritsis AP, Yung WKA, Jaeckle KA, et al: Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39:921-925, 1996
23. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10:766-771, 1992
24. Sanson M, Ameri A, Monjour A, et al: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II trial. Eur J Cancer 32A:2229-2235, 1996
25. Rodriguez LA, Prados M, Silver P, et al: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420-2423, 1989
26. Newton HB, Junck L, Bromberg J, et al: Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40:1743-1746, 1990
27. Vertosick FT, Selker RG, Pollack IF, et al: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy. Preliminary results in a series of "failed" patients. Neurosurgery 30:897-903, 1992
28. Couldwell WT, Hinton DR, Surnock AA, et al: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen: Advances in brief. Clin Cancer Res 2:619-622, 1996
29. Rahr HB, Sorensen JV: Venous thromboembolism and cancer. Blood Coagul Fibrinolysis 3:451-460, 1992
30. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984
31. Jordan C, Fritz N, Tormey D: Long term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 45:4517-4519, 1987
32. Ruiz MA, Marugan I, Estelles A, et al: The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients. Cancer 63:643-648, 1989
33. Brandes AA, Scelzi E, Salmistraro G, et al: Incidence and risk of thromboembolism during treatment of high grade gliomas: A prospective study. Eur J Cancer 33:1592-1596, 1997
34. Coyle T, Bushunow P, Winfield J, et al: Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. Cancer 69:2532-2540, 1992
35. Wong ET, Hess KR, Gleason J, et al: Time to tumor progression as a measure of efficacy in phase II chemotherapy trials for recurrent malignant gliomas. Proc Am Soc Clin Oncol 15:153, 1996 (abstr 277)
36. Rajan B, Ross G, Lim CC, et al: Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy. Eur J Cancer 30A:1809-1815, 1994
37. Greenberg D, Carpenter C, Messing R, et al: Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC 12 neurosecretory cell lines. Cancer Res 47:70-74, 1987
38. Schwartsmann G, Mans D, Machado V, et al: Enhanced disposition of etoposide in the cerebrospinal fluid by high dose tamoxifen in patients with progressive malignant gliomas. Proc Am Soc Clin Oncol 14:153, 1995 (abstr 310)